Jennifer Eads, MD

Articles by Jennifer Eads, MD

$Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.$

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers

ByJennifer Eads, MD

June 2nd 2026

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma

ByJennifer Eads, MD

September 11th 2024

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine

Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

ByJennifer Eads, MD

June 4th 2024

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Dr. Eads Discusses the Classification of Gastrointestinal NETs

ByJennifer Eads, MD

January 12th 2018

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal neuroendocrine tumors.